专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20060209938A1 Methods and circuits for power management in a transceiver 有权
标题翻译：收发器电源管理的方法和电路
公开(公告)号：US20060209938A1
公开(公告)日：2006-09-21
申请号：US11440151
申请日：2006-05-25
申请人： Xi Chen
发明人： Xi Chen
IPC分类号： H04B1/38
CPC分类号： H04L1/243
摘要： A transceiver circuit having 10 mb and 100 mb transmit and receive circuitries using the power saving methods of the present invention is disclosed. The power consumption of the transceiver circuit can be significantly reduced by providing each defined subcircuit with its own power supply and means of activation and deactivation. However, the method for activating and deactivating digital subcircuits and analog subcircuits are different and therefore different types of control signals and methods are provided. Furthermore, there are two general types of power-saving situations. The first type is near total circuit power-down and the second type is partial circuit power-down. The present invention in yet another embodiment discloses a method for minimizing energy usage during idle period.
摘要翻译：公开了使用本发明的省电方法的具有10mb和100mb发送和接收电路的收发器电路。通过为每个定义的子电路提供自己的电源和激活和停用的手段，可以显着减少收发器电路的功耗。然而，用于激活和停用数字子电路和模拟子电路的方法是不同的，因此提供了不同类型的控制信号和方法。此外，省电情况有两种。第一种类型是接近总电路掉电，第二种是部分电路掉电。在另一个实施例中的本发明公开了一种在空闲时段期间最小化能量使用的方法。

72. 发明授权

US07101887B2 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands 失效
标题翻译： 1-苯基-4-苄基哌嗪多巴胺受体亚型特异性配体
公开(公告)号：US07101887B2
公开(公告)日：2006-09-05
申请号：US11167735
申请日：2005-06-27
申请人： Andrew Thurkauf , Xi Chen
发明人： Andrew Thurkauf , Xi Chen
IPC分类号： A61K31/495 , C07D295/076
CPC分类号： C07D295/073 , A61K31/495 , C07C2603/08 , C07D295/096 , C07D295/112 , C07D295/135
摘要： Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R1 is halogen or C1–C4 alkyl; and R2 and R3 are the same or different and represent hydrogen, halogen, C1–C4 alkyl, C1–C4 alkoxy, alkylthio, hydroxy, amino, mono(C1–C4)alkylamino, di(C1–C4)alkylamino, or R2 and R3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.
摘要翻译：公开了下式的化合物或其药学上可接受的加成盐，其中：R 1是卤素或C 1 -C 4烷基; R 2和R 3相同或不同，表示氢，卤素，C 1 -C 4烷基，烷基，C 1 -C 4烷氧基，烷硫基，羟基，氨基，单（C 1 -C 4 - ）烷基氨基，二（C 1 -C 4 - ）烷基氨基或R 2和R 3一起代表一个与它们所连接的苯环一起形成萘基部分的4碳亚烯基部分，该化合物可用于治疗神经疾病疾病如精神分裂症，精神病抑郁症和躁狂症。

73. 发明授权

US06288230B1 2-(2, 3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands 失效
标题翻译： 2-（2,3-二氢苯并呋喃-5-基）-4-氨基甲基咪唑：多巴胺受体亚型特异性配体
公开(公告)号：US06288230B1
公开(公告)日：2001-09-11
申请号：US09408035
申请日：1999-09-29
申请人： Xi Chen , Xiao-shu He
发明人： Xi Chen , Xiao-shu He
IPC分类号： C07D24102
CPC分类号： C07D405/04 , C07D405/14
摘要： Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof wherein: n is an integer; R1 represents an organic or inorganic group; R2 represents halogen or C1-C6 alkyl; RN is an alkylene carrying a substituted piperazine, piperidine, or tetrahydropyridine; and R4 is hydrogen or C1-C6 alkyl, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.
摘要翻译：公开了下式的化合物或其药学上可接受的酸加成盐，其中：n为整数; R1为有机或无机基团; R2为卤素或C1-C6烷基; RN为带有取代哌嗪的亚烷基，哌啶，或四氢吡啶; 和R 4是氢或C 1 -C 6烷基，该化合物可用于治疗和/或预防神经心理障碍，包括但不限于精神分裂症，躁狂症，痴呆，抑郁，焦虑，强迫行为，物质滥用，帕金森氏样运动与使用神经安定药相关的疾病和运动障碍。

74. 发明授权

US06221869B1 N-aminoalkyldibenzothiophenecarboxamides new dopamine receptor subtype specific ligands 失效
标题翻译： N-氨基烷基二苯并噻吩甲酰胺新型多巴胺受体亚型特异性配体
公开(公告)号：US06221869B1
公开(公告)日：2001-04-24
申请号：US09499066
申请日：2000-02-04
申请人： Jun Yuan , Xi Chen
发明人： Jun Yuan , Xi Chen
IPC分类号： A61K31496
CPC分类号： C07D409/12 , B32B15/08 , C07D333/76 , C08G73/10 , C08G73/1007 , C08G73/101 , H05K1/0346
摘要： Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof, wherein: R1, R2, R3, R4 are the same or different and represent hydrogen, C1-C6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-C6 alkoxy, —O2CR′, —NHCOR′, —COR′, —SOmR′, where R′ is C1-C6 alkyl and wherein m is 0, 1 or 2; or R1, R2, R3, R4 independently represent —CONR′R″, or —NR′R″ where R′ and R″ independently represent hydrogen or C1-C6 alkyl; R5 is hydrogen or C1-C6 alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.
摘要翻译：公开了下式的化合物或其药学上可接受的酸加成盐，其中：R 1，R 2，R 3，R 4相同或不同，表示氢，C 1 -C 6烷基，卤素，羟基，氨基，氰基，硝基，三氟甲基，三氟甲氧基，C 1 -C 6烷氧基，-O 2 CR'，-NHCOR'，-COR'，-SO m R'，其中R'是C 1 -C 6烷基，其中m是0,1或2; 或R 1，R 2，R 3，R 4独立地表示-CONR'R“，或-NR'R”，其中R'和R“独立地表示氢或C 1 -C 6烷基; R 5是氢或C 1 -C 6烷基; R代表氨基烷基，该化合物可用于治疗情感障碍如精神分裂症，抑郁症，阿尔茨海默氏病，运动障碍如帕金森综合征和肌张力障碍，以及其他对多巴胺能阻滞作用的药物滥用和强迫症。此外，本发明的化合物可用于治疗与使用常规精神抑制剂相关的锥体束外副作用。

75. 发明授权

US6025493A N-piperazinylalkyl-2-anthracenecarboxamides 失效
标题翻译： N-哌嗪基烷基-2-蒽基甲酰胺
公开(公告)号：US6025493A
公开(公告)日：2000-02-15
申请号：US264448
申请日：1999-03-08
申请人： Jun Yuan , Xi Chen
发明人： Jun Yuan , Xi Chen
IPC分类号： C07D295/12 , A61K31/44 , A61K31/445 , A61K31/451 , A61K31/495 , A61P25/00 , A61P25/18 , A61P25/20 , A61P25/28 , A61P25/30 , C07D211/14 , C07D211/28 , C07D211/70 , C07D217/02 , C07D295/13 , C07D295/15
CPC分类号： C07D295/13 , C07D211/14 , C07D211/70 , C07C2103/24
摘要： Disclosed arm compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof, wherein: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are the same or different and represent hydrogen, C.sub.1 -C.sub.6 allyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C.sub.1 -C.sub.6 alkoxy, --O.sub.2 CR', --NHCOR', --COR', --SO.sub.m R', where R' is C.sub.1 -C.sub.6 alkyl and wherein m is 0, 1 or 2; orR.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 independently represent --CONR'R", or --NR'R" where R' and R" independently represent hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.10 is hydrogen or C.sub.1 -C.sub.6 alkyl; andR represents an aminoalkyl group;which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.
摘要翻译：公开的下式化合物或其药学上可接受的酸加成盐，其中：R1，R2，R3，R4，R5，R6，R7，R8和R9相同或不同，代表氢，C1-C6烯丙基，卤素，羟基，氨基，氰基，硝基，三氟甲基，三氟甲氧基，C 1 -C 6烷氧基，-O 2 CR'， - NHCOR'，-COR'，-SO m R'，其中R'是C 1 -C 6烷基，其中m是0,1或 2; 或R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8和R 9独立地表示-CONR'R“或-NR'R”，其中R'和R“独立地表示氢或C1-C6烷基; R 10是氢或C 1 -C 6烷基; R表示氨基烷基; 哪些化合物可用于治疗情感障碍如精神分裂症，抑郁症，阿尔茨海默氏病，运动障碍如帕金森综合征和肌张力障碍，以及其他对多巴胺能阻滞作用的药物滥用和强迫症。此外，本发明的化合物可用于治疗与使用常规精神抑制剂相关的锥体束外副作用。

76. 发明授权

US6015900A N-aminoalkylfluorenecarboxamides 失效
标题翻译： N-氨基烷基芴甲酰胺
公开(公告)号：US6015900A
公开(公告)日：2000-01-18
申请号：US43022
申请日：1998-11-23
申请人： Jun Yuan , Xi Chen
发明人： Jun Yuan , Xi Chen
IPC分类号： C07D295/12 , A61K31/00 , A61K31/38 , A61K31/381 , A61K31/445 , A61K31/451 , A61K31/495 , A61K31/496 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/26 , A61P25/28 , A61P43/00 , C07D211/14 , C07D211/18 , C07D211/32 , C07D211/70 , C07D217/02 , C07D217/04 , C07D295/13 , C07D333/20 , C07D333/34 , C07D295/15
CPC分类号： C07D295/13 , C07D211/14 , C07D211/32 , C07D211/70 , C07D217/02 , C07C2103/18
摘要： Disclosed are compounds of formula (I) or the pharmaceutically acceptable salts thereof wherein: ##STR1## G represents a group of the formula (a), (b) or (c) where R.sub.a and R.sub.b represent hydrogen, or organic or inorganic substituents; A is an optionally substituted alkylene; R.sub.1, R.sub.2, R.sub.3, R.sub.4 represent organic or inorganic substituents; R.sub.5 is hydrogen or lower alkyl; R.sub.6 and R.sub.7 independently represent hydrogen, lower alkyl; or together form a ring of 5-8 members; Z is nitrogen or carbon; and W is optionally susbtituted aryl or heteroaryl. Compounds of the present invention demonstrate high affinity and selectivity in binding to the D.sub.3 receptor subtype.
摘要翻译： PCT No.PCT / US96 / 14650 Sec。 371日期：1998年11月23日 102（e）1998年11月23日日期PCT 1996年9月12日PCT公布。出版物WO97 / 10229 日期1997年3月20日公开是式（I）化合物或其药学上可接受的盐，其中：G表示式（a），（b）或（c）的基团，其中R a和R b表示氢，或有机或无机取代基; A是任选取代的亚烷基; R1，R2，R3，R4代表有机或无机取代基; R5是氢或低级烷基; R6和R7独立地表示氢，低级烷基; 或一起组成5-8名成员的戒指; Z是氮或碳; 并且W是任选的取代的芳基或杂芳基。本发明化合物在与D3受体亚型结合中表现出高亲和力和选择性。

77. 发明授权

US5977367A N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands 失效
标题翻译： N-氨基烷基二苯并呋喃甲酰胺; 新的多巴胺受体亚型特异性配体
公开(公告)号：US5977367A
公开(公告)日：1999-11-02
申请号：US005285
申请日：1998-01-09
申请人： Jun Yuan , Xi Chen
发明人： Jun Yuan , Xi Chen
IPC分类号： A61K31/34 , A61K31/343 , A61K31/443 , A61K31/4525 , A61K31/496 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/26 , A61P25/28 , A61P43/00 , C07D307/91 , C07D405/12
CPC分类号： C07D307/91 , A61K31/496 , C07D405/12
摘要： Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof, wherein: R.sub.1, R.sub.2, R.sub.3, R.sub.4 are the same or different and represent hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C.sub.1 -C.sub.6 alkoxy, --O.sub.2 CR', --NHCOR', --COR', --SO.sub.m R', where R' is C.sub.1 -C.sub.6 alkyl and wherein m is 0, 1 or 2; orR.sub.1, R.sub.2, R.sub.3, R.sub.4 independently represent --CONR'.sub.m, or --NR'.sub.m where m is 0, 1 or 2 and R' is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.5 is hydrogen or C.sub.1 -C.sub.6 alkyl; andR represents an aminoalkyl group,which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.
摘要翻译：公开了下式的化合物或其药学上可接受的酸加成盐，其中：R 1，R 2，R 3，R 4相同或不同，表示氢，C 1 -C 6烷基，卤素，羟基，氨基，氰基，硝基，三氟甲基，三氟甲氧基，C 1 -C 6烷氧基，-O 2 CR'，-NHCOR'，-COR'，-SO m R'，其中R'是C 1 -C 6烷基，其中m是0,1或2; 或R 1，R 2，R 3，R 4独立地表示-CONR'm或-NR'm，其中m为0,1或2，R'为氢或C 1 -C 6烷基; R5是氢或C1-C6烷基; R代表氨基烷基，该化合物可用于治疗情感障碍如精神分裂症，抑郁症，阿尔茨海默氏病，运动障碍如帕金森综合征和肌张力障碍，以及其他对多巴胺能阻滞作用的药物滥用和强迫症。此外，本发明的化合物可用于治疗与使用常规精神抑制剂相关的锥体束外副作用。

78. 发明授权

US5932734A N-aminoalkylfluorenecarboxamides 失效
标题翻译： N-氨基烷基芴甲酰胺
公开(公告)号：US5932734A
公开(公告)日：1999-08-03
申请号：US908361
申请日：1997-08-07
申请人： Jun Yuan , Xi Chen
发明人： Jun Yuan , Xi Chen
IPC分类号： C07D295/12 , A61K31/00 , A61K31/38 , A61K31/381 , A61K31/445 , A61K31/451 , A61K31/495 , A61K31/496 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/26 , A61P25/28 , A61P43/00 , C07D211/14 , C07D211/18 , C07D211/32 , C07D211/70 , C07D217/02 , C07D217/04 , C07D295/13 , C07D333/20 , C07D333/34 , C07D295/15
CPC分类号： C07D295/13 , C07D211/14 , C07D211/32 , C07D211/70 , C07D217/02 , C07C2103/18
摘要： Disclosed are compounds of the formula ##STR1## or the pharmaceutically acceptable salts thereof wherein: G represents a group of the formula ##STR2## where R.sub.a and R.sub.b represent hydrogen, or organic or inorganic substituents;A is an optionally substituted alkylene;R.sub.1, R.sub.2, R.sub.3, R.sub.4 represent organic or inorganic substituents;R.sub.5 is hydrogen or lower alkyl;R.sub.6 and R.sub.7 independently represent hydrogen, lower alkyl; or together form a ring of 5-8 members;Z is nitrogen or carbon; andW is optionally substituted aryl or heteroaryl. Compounds of the present invention demonstrate high affinity and selectivity in binding to the D.sub.3 receptor subtype.
摘要翻译：公开了下式的化合物或其药学上可接受的盐，其中：G表示下式的基团，其中R a和R b表示氢，或有机或无机取代基; A是任选取代的亚烷基; R1，R2，R3，R4代表有机或无机取代基; R5是氢或低级烷基; R6和R7独立地表示氢，低级烷基; 或一起组成5-8名成员的戒指; Z是氮或碳; W是任选取代的芳基或杂芳基。本发明化合物在与D3受体亚型结合中表现出高亲和力和选择性。

79. 发明授权

US5710274A N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands 失效
标题翻译： N-氨基烷基二苯并呋喃甲酰胺; 新的多巴胺受体亚型特异性配体
公开(公告)号：US5710274A
公开(公告)日：1998-01-20
申请号：US608259
申请日：1996-02-28
申请人： Jun Yuan , Xi Chen
发明人： Jun Yuan , Xi Chen
IPC分类号： A61K31/34 , A61K31/343 , A61K31/443 , A61K31/4525 , A61K31/496 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/26 , A61P25/28 , A61P43/00 , C07D307/91 , C07D405/12 , C07D209/00 , C07D241/02 , C07D401/00
CPC分类号： C07D307/91 , A61K31/496 , C07D405/12
摘要： Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof, wherein: R.sub.1, R.sub.2, R.sub.3, R.sub.4 are the same or different and represent hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C.sub.1 -C.sub.6 alkoxy, --O.sub.2 CR', --NHCOR', --COR', --SO.sub.m R', where R' is C.sub.1 -C.sub.6 alkyl and wherein m is 0, 1, or 2; or R.sub.1, R.sub.2, R.sub.3, R.sub.4 independently represent --CONR'.sub.m, or --NR'.sub.m where m is 0, 1 or 2 and R' is hydrogen or C.sub.1 -C.sub.6 alkyl; R.sub.5 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockage such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.
摘要翻译：公开了下式的化合物或其药学上可接受的酸加成盐，其中：R 1，R 2，R 3，R 4相同或不同，表示氢，C 1 -C 6烷基，卤素，羟基，氨基，氰基，硝基，三氟甲基，三氟甲氧基，C 1 -C 6烷氧基，-O 2 CR'， - NHCOR'， - CON'，-SO m R'，其中R'是C 1 -C 6烷基，其中m是0,1或2; 或R 1，R 2，R 3，R 4独立地表示-CONR'm或-NR'm，其中m为0,1或2，R'为氢或C 1 -C 6烷基; R5是氢或C1-C6烷基; 并且R代表氨基烷基，该化合物可用于治疗情感障碍如精神分裂症，抑郁症，阿尔茨海默氏病，运动障碍如帕金森综合征和肌张力障碍，以及其他对多巴胺能阻塞作用的疾病，例如药物滥用和强迫症。此外，本发明的化合物可用于治疗与使用常规精神抑制剂相关的锥体束外副作用。

80. 发明公开

US20240311645A1 METHODS AND SYSTEMS FOR FEDERATED LEARNING USING FEATURE NORMALIZATION 审中-公开
公开(公告)号：US20240311645A1
公开(公告)日：2024-09-19
申请号：US18182744
申请日：2023-03-13
申请人： Guojun Zhang , Alex Bie , Mahdi Beitollahi , Xi Chen
发明人： Guojun Zhang , Alex Bie , Mahdi Beitollahi , Xi Chen
IPC分类号： G06N3/098
CPC分类号： G06N3/098
摘要： Methods and systems for federated learning using feature normalization are disclosed. A client implements a local model including at least: a feature extraction subnetwork to extract a feature vector from input data, a normalization layer to normalize the feature vector, and a final layer to generate a prediction output from the normalized feature vector. The local model is initialized using a set of global parameters received from a central server. The local model is updated using data sampled from a local dataset. Information about a state of the updated local model is transmitted to the central server.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式